Promising Biotech Stocks To Watch Now – November 5th

Moderna, AbbVie, Amgen, Gilead Sciences, Revolution Medicines, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that use biological science to develop products or services, such as medicines, diagnostics, and research tools. For investors, they can offer significant growth potential, but their value may be especially volatile because it often depends on clinical-trial results, regulatory decisions, and the companies’ ability to fund development. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

MRNA stock traded down $14.55 during trading on Thursday, hitting $243.83. The stock had a trading volume of 5,530,874 shares, compared to its average volume of 12,602,524. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna has a twelve month low of $22.28 and a twelve month high of $261.00. The stock has a market capitalization of $97.35 billion, a P/E ratio of -30.52 and a beta of 1.16. The company’s 50-day moving average price is $187.78 and its two-hundred day moving average price is $89.46.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of AbbVie stock traded down $0.38 during mid-day trading on Thursday, reaching $294.45. 2,544,819 shares of the stock traded hands, compared to its average volume of 6,328,213. The stock has a market capitalization of $520.23 billion, a PE ratio of 50.63, a PEG ratio of 1.30 and a beta of 0.20. The business has a 50-day moving average of $270.80 and a 200 day moving average of $238.28. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $302.93.

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Shares of NASDAQ:AMGN traded down $9.44 during trading on Thursday, reaching $469.04. The stock had a trading volume of 1,498,688 shares, compared to its average volume of 2,752,142. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen has a 1-year low of $312.39 and a 1-year high of $483.99. The stock has a market cap of $253.58 billion, a PE ratio of 27.19, a PEG ratio of 3.38 and a beta of 0.43. The business has a fifty day moving average price of $421.56 and a 200-day moving average price of $376.90.

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

NASDAQ GILD traded down $3.13 during mid-day trading on Thursday, hitting $171.35. The stock had a trading volume of 3,359,663 shares, compared to its average volume of 6,820,989. The stock has a market capitalization of $212.53 billion, a price-to-earnings ratio of -54.29 and a beta of 0.35. The firm’s 50 day moving average is $152.29 and its 200 day moving average is $140.52. Gilead Sciences has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95.

Revolution Medicines (RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Shares of Revolution Medicines stock traded down $12.99 during trading hours on Thursday, reaching $186.71. 2,718,943 shares of the company were exchanged, compared to its average volume of 2,782,762. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines has a 1 year low of $58.91 and a 1 year high of $224.31. The firm has a market cap of $40.02 billion, a PE ratio of -21.04 and a beta of 1.44. The stock’s fifty day moving average is $198.21 and its 200 day moving average is $156.90.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

REGN stock traded down $12.48 during trading on Thursday, hitting $918.19. 543,384 shares of the company’s stock were exchanged, compared to its average volume of 829,131. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $991.73. The business has a 50-day moving average price of $800.69 and a two-hundred day moving average price of $741.11. The stock has a market capitalization of $94.54 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.45 and a beta of 0.10.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX stock traded down $3.02 during trading hours on Thursday, hitting $546.02. The stock had a trading volume of 696,879 shares, compared to its average volume of 1,392,976. Vertex Pharmaceuticals has a twelve month low of $406.67 and a twelve month high of $568.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 2.74. The firm has a market capitalization of $138.58 billion, a PE ratio of 35.07, a PEG ratio of 2.56 and a beta of 0.28. The stock’s 50 day moving average is $522.90 and its 200 day moving average is $480.92.